Gastrointestinal Cancers

CAN-2409 has been associated with improved survival among patients with non-metastatic, borderline resectable pancreatic ductal adenocarcinoma.

The novel treatment, zanidatamab, has been submitted to the FDA via a Biologics License Application for patients with HER2-positive biliary tract cancer.

After five years of being cancer-free, my oncologist said I'm graduated and can live my life freely.

Enhertu has been approved by the FDA for certain patients with unresectable or metastatic HER2-positive solid tumors.

When I was my husband's caregiver, I tried to make things comfortable, but I'm not sure if the drugs and bedpans could ever make it right.

The GI cancer space has “made huge strides” in recent years, which opened more options for patients with a type of esophageal cancer, an expert said.

Here are four signs of your doctor not listening and four things I do when they don't listen to me.

Certain oral chemotherapies may cause hand-foot syndrome, but reducing the dose of the drug allows it to heal, an expert told CURE®.

Moderate multivitamin use was associated with a decreased risk of death in patients with colorectal cancer, though more research is needed, an expert said.

The Food and Drug Administration approved Tevimbra for pretreated metastatic or unresectable esophageal squamous cell carcinoma.

Although many hate drinking the prep for colonoscopies, I view it as a privilege.

From TikTok singer Cat Janice dying of cancer to Taylor Swift giving a 9-year-old with brain cancer the “22” hat during a recent concert, here is what’s happening in the oncology space this week.

The Food and Drug Administration has accepted a Biologics License Application for Tevimbra with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

After I was diagnosed with colon cancer, I learned to take care of myself more and be more outspoken than ever before.

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.

Spending a fourth of my life as a cancer survivor, I’ve learned a few lessons along the way.

I wondered how much I could contribute to cholangiocarcinoma awareness, but determined that if I help just one person, then that's a success.

The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has announced.

Country singer Toby Keith died Monday after receiving a stomach cancer diagnosis in 2022.

A vaccine for pancreatic and colorectal cancers is showing promise, but potential availability of the drug is likely several years away, an expert said.

My wife's simple sentence to me ended up saving my life from colorectal cancer.

Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

Circulating tumor DNA-based minimal residual disease lent insight into which patients with stage 2/3 colorectal cancer may be at higher risk for recurrence and which could benefit from postsurgical chemotherapy.

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab.

In patients with esophageal squamous cell carcinoma, the combination of Tecentriq, tiragolumab and chemotherapy improved survival outcomes, research found.

In patients with TRK fusion GI cancers, Vitrakvi continued to show improvements regarding responses to treatment, survival and safety, research found.

The use of the chemotherapy regimen FOLFOXIRI plus Avastin has increased from 2013 to 2022 in patients with metastatic colorectal cancer, particularly in patients aged 50 years and younger.

Certain patients with metastatic colorectal cancer were more likely to have long-term remission to Stivarga treatment, recent research showed.

Imfinzi plus chemotherapy, when given before surgery, improved pathologic complete response rates, regardless of region, in certain patients with gastric or gastroesophageal junction cancers.

Treatment with Opdivo and chemotherapy improved survival in patients with gastrointestinal cancers, compared with chemotherapy alone, according to a phase 3 trial.